MMP9 and triple-A syndrome: We hypothesized that treatment with ATRA attenuates the progression of Angiotensin II (Ang II)-induced AAA by inhibiting the expression of MMP2, MMP9, and angiotensin II receptor type 1 (AT1) in ApoE−/− mice.